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Abstract Osteoporotic fracture (OF) is one of the major
causes of morbidity and mortality in industrialized countries.
Switzerland is among the countries with the greatest risk.
Our aim was (1) to calculate the FRAX® in a selected
Swiss population the day before the occurrence of an OF
and (2) to compare the results with the proposed Swiss
FRAX® thresholds. The Swiss Association Against Osteo-
porosis proposed guidelines for the treatment of osteoporo-
sis based on age-dependent thresholds. To identify a
population at a very high risk of osteoporotic fracture, we
included all consecutive patients in the active OF pathway
cohort from the Lausanne University Hospital, Switzerland.
FRAX® was calculated with the available data the day
before the actual OF. People with a FRAX® body mass
index (BMI) or a FRAX® (bone mineral density) BMD
lower than the Swiss thresholds were not considered at
high risk. Two-hundred thirty-seven patients were included
with a mean age of 77.2 years, and 80 % were female.
Major types of fracture included hip (58 %) and proximal
humerus (25 %) fractures. Mean FRAX® BMI values were
28.0, 10.0, 13.0, 26.0, and 37.0 % for age groups 50–59,
60–69, 70–79, and 80–89 years old, respectively. Fifty
percent of the population was not considered at high risk
by the FRAX® BMI. FRAX® BMD was available for 95
patients, and 45 % had a T score<−2.5 standard deviation.
Only 30 % of patients with a normal or osteopenic BMD
were classified at high risk by FRAX® BMD. The current
proposed Swiss thresholds were not able to classify at high
risk in 50 to 70 % of the studied population the day before
a major OF.
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Introduction
Osteoporotic fracture (OF) is one of the major causes of
morbidity and mortality in industrialized countries, with
Switzerland among the countries with the greatest risk [1].
Recent studies have shown that 30 to 54 % of osteopo-
rotic fractures occur in individuals whose bone mineral
density (BMD) T score is higher than the cutoff of −2.5
standard deviation (SD), with some falling within the
range defined for osteopenia (T0−2.5 to −1.0 SD), or
“normal” range (T>−1.0 SD) [2–4].
To identify major clinical risk factors for OF, data from
20 studies, incorporating more than 275,000 patients, were
analyzed [5]. The validation analysis included results from
the Swiss SEMOF cohort [4, 6]. Factors such as prior
fragility fracture after the age of 50 years old, age, sex, body
mass index (BMI), use of glucocorticoids, secondary osteo-
porosis, rheumatoid arthritis, parental history of hip fracture,
current smoking, and alcohol intake were considered. These
factors were identified as clinical predictors of osteoporotic
fracture independently from BMD [5]. Taking into account
local epidemiological data for specific fracture outcome and
mortality, a Swiss-specific FRAX® model was proposed [6].
The FRAX® can be calculated either incorporating (FRAX®
BMD) or not incorporating the BMD (FRAX® BMI).
The challenge is now to find the ideal FRAX® thresholds,
country by country, from a health economic perspective to
determine the best intervention threshold. Ideally, an appro-
priate threshold should be established using population-
based prospective studies, but such studies tend to be long
and quite expensive. Before having these results, some
countries have decided to establish new guidelines for the
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identification of individuals at high fracture risk based
on previously existing guidelines and some local epidemio-
logical data.
With these considerations, the Swiss Association
Against Osteoporosis (SVGO) proposed new guidelines
for the treatment of osteoporosis based on age-dependent
thresholds according to the new Swiss FRAX® model
(www.SVGO.ch).
The aim of our study was to calculate FRAX® in a very
high-risk population with a recent suspected OF and to
compare the results with the proposed Swiss thresholds.
Materials and methods
Patients and measurements
To define a population at high risk of osteoporotic fracture,
we selected patients in the active OF pathway cohort from
the Lausanne University Hospital, Switzerland. For this
study, patients were selected with the following inclusion
criteria:
1. They should have been hospitalized at the Lausanne
University Hospital for a suspected OF (hip, spine,
pelvis, forearm, proximal humerus) between November
2008 and April 2009.
2. They should have been included in the database of the
active management protocol for OF [2, 7, 8].
3. They should have given their agreement to participate in
this study.
During this active management, a specific question-
naire, including all data for the FRAX® score calcula-
tion, was completed. We met 608 consecutive patients
during the study period. Only patients with all data
available for the FRAX® calculation score were includ-
ed in the analysis. One-hundred eighty-seven patients
had missing data (weight and height principally). All
patients included in this study had a diagnosis of oste-
oporotic fracture, suspected by a clinician expert in
osteoporosis management, while 85 were not suspected
to have typical OF.
To calculate the FRAX® the day before the actual frac-
ture, we did not consider the actual fracture as a previous
fracture. Patients with a traumatic fracture, younger than
50 years old and older than 90 years old, or currently or
previously on specific treatment for osteoporosis (e.g.,
bisphosphonate or teriparatide) were excluded, as proposed
in the FRAX® model (24 patients were >90 or <40 and
75 years old and have already received a specific treatment).
Finally, out of the 608 consecutive patients considered, 237
met the inclusion criteria, of whom 95 had undergone BMD
measurement.
Swiss thresholds and FRAX® calculations
The threshold limits proposed by the SVGO depend upon
the patient’s age (Table 1). The thresholds were calculated
by the FRAX® Swiss calculator using a fictitious population
that had suffered one previous fracture (translating existing
guidelines) with a standard BMI.
To test the Swiss thresholds, we calculated the FRAX®BMI.
The Swiss-specific calculation was generated using the WHO
FRAX® website. Patients with a result lower than their “range
of age thresholds” were considered not detected at high risk by
FRAX® the day before a suspected OF. If patients underwent a
rapid dual-energy X-ray absorptiometry (DXA) (not more than
3 months after the actual fracture), we included the femoral
neck Tscore and calculated the FRAX®BMD. Patients with a T
score>−2.5 (lumbar spine and/or femoral neck and/or total hip)
and/or a FRAX® BMD lower than their range of age thresholds
were considered not detected at high risk neither by FRAX®
BMD nor by BMD the day before a suspected OF.
Statistical analysis
Studied parameters were tested for normality, and descrip-
tive statistics as mean ±SD were provided. Results compar-
ing Swiss thresholds and FRAX® BMI are presented in
absolute number and percentage of patients. The different
models were tested using the SVGO thresholds.
Results
The mean age of the population (n0237) was 77.2±9.4 years,
and 80 % were female. The mean weight and height
were 66.4±18.8 kg and 162.3±14.0 cm, respectively. The
major fracture site was the hip (58.1 %) followed by the
proximal humerus (25.0 %), the forearm (22.7 %), the spine
(11.0 %), and the pelvis (8.2 %). Only one FRAX® clinical risk
factor was present in 41.7 % of the population and one or more
FRAX® clinical risks factors in 70.8 % of the population.
Clinical risk factors for osteoporosis were more prevalent in
Table 1 Lower threshold limits before initiating specific treatment for
osteoporotic fractures in Switzerland
Age (in years) Threshold (all major osteoporotic fractures) (%)
50 >10
60 >15
70 >30
80 >40
Based upon calculating the 10-year absolute probability of fracture
using the FRAX® calculator for Switzerland
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the youngest group (50–59 years old) than in the oldest group
(Table 2).
The mean FRAX® BMI (the 10-year probability of a major
OF percentage) was 28.0 %. The mean FRAX® BMI was
10.0, 13.0, 26.0, and 37.0 % for those aging 50–59, 60–69,
70–79, and 80–89 years old, respectively (Fig. 1). According
to the Swiss thresholds, 47.0, 57.0, 56.0, and 54.5 % of
patients (for ages 50–59, 60–69, 70–79, and 80–89 years
old, respectively) were not considered at high risk by the
FRAX® BMI the day before a major OF. Results by fracture
site are shown in Table 3. A DXAwas realized in 95 patients,
of whom 45 % had an osteoporosis with a T score<−2.5 SD
(lumbar spine and/or femoral neck and/or total hip).
Patients with a normal or osteopenic BMD had a FRAX®
BMD lower than the Swiss age thresholds in 50, 71, 85, and
84 % for the groups aging 50–59, 60–69, 70–79, and 80–
89 years old, respectively. In other words, the FRAX® BMD
identified less than 30 % of patients with a normal or osteo-
penic BMD the day before an OF to be at high risk of fracture.
Discussion
The development of new scientifically supported treatments
against osteoporosis, and society’s increasing preoccupation
with the economic costs of osteoporotic fractures, has brought
about the need for not only effective, but also efficient man-
agement of osteoporosis [3, 9–13]. The new FRAX® model
for the prediction of osteoporotic fractures is the cheapest and
is probably an efficient means to identify populations at low,
medium, or high risk for an OF. FRAX® has been developed
to predict the 10-year fracture risk probability and to improve
the positive predictive value of BMD [5]. It is a powerful tool
that can be developed and adapted for any specific country to
calculate its “local” risk [3]. In a second step, thresholds and
FRAX® prediction have to be calibrated and established,
thanks to prospective studies. Sometimes, the FRAX® cali-
bration has changed the initial FRAX® after adjustment by
specific prospective studies. In Canada, the Manitoba cohort
and the Canadian Multicentre Osteoporosis study (CaMOs)
cohort allowed to calibrate the FRAX® Canadian prediction.
In the CaMOs, FRAX® based on clinical factor risks (CRFs)
and BMD was found to be a more accurate predictor of
fracture risk than BMD alone or FRAX® estimated on CRFs
alone [14]. In France, two independent cohorts, Os des
Femmes de Lyon (OFELY) [15] and a subset of the Osteopo-
rosis and Ultrasound Study (OPUS) [16], compared the ob-
served incidence of fracture with the predicted probability of
fracture from FRAX®. In the OFELY study, among women
≥65 years old with low BMD values, the 10-year predicted
probability of major osteoporotic fracture with BMD was
48 % lower than the observed incidence of fracture. In the
Table 2 FRAX® clinical risk
factors
RA rheumatoid arthritis
Age/risk
factors
Previous
fracture (%)
Parental hip
fracture (%)
Corticotherapy (%) RA (%) Alcohol (%) Tobacco
(%)
50–59 (n017) 66.0 22 .0 5.5 0.0 50.0 55.0
60–69 (n037) 45.0 9.0 13.0 3.0 42.0 42.0
70–79 (n063) 55.0 4 .0 14.0 2.8 13.0 24.0
80–89 (n0120) 52.0 12.0 5.6 0 .0 4.8 7.2
Fig. 1 Results of FRAX® BMI
for the overall population by
age group. yo Years old
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OPUS cohort (with a following of 6 years), FRAX® with or
without BMD could not predict hip OFs. Nevertheless, we
have to interpret these external validations of FRAX® with
caution as mentioned by Kanis et al. [17]. In Switzerland,
there is no post-FRAX® model prospective data available yet.
The thresholds proposed by SVGO were calculated by age
group to account for major OFs. Our objective was to calcu-
late FRAX® (and not to do an external validation) and to
compare results with these thresholds within a population that
had actually suffered recent suspected OFs. Half of the pop-
ulation we studied had a FRAX® BMI value below the Swiss
thresholds. Regarding the site of the osteoporotic fracture
(Table 3), we cannot draw conclusions as the number of
patients per group is too small.
Interestingly, in the subpopulation with a DXA measure-
ment, BMD alone identified 45 % of the population to be at
high fracture risk. FRAX® BMD has identified at high risk
less than 30 % of patients with a normal or osteopenic BMD
the day before a suspected OF. Finally, in our population,
FRAX® BMD does not seem to improve the detection of
patients at high risk comparatively with BMD. Some can
argue that in our country, BMD is limited within the condi-
tion of reimbursement. However, in all age groups, 45 to
66 % of patients could have had a reimbursement only based
on one clinical risk factor: a previous low traumatic fracture
(Table 2). This is the only one homogenous CRF regarding
age group in our population. Moreover, in our younger
population, we found more CRFs than others and lower T
scores. These observations could probably explain the high
FRAX® BMI found in this subgroup. Among the limitations
of FRAX®, some can argue that using neck BMD as the sole
BMD site to calculate the probability of fracture may not be
appropriate in all situations [18]. We tested if our patients
could have had a different result if the FRAX® BMD was
performed with the result of the spine BMD (for those with a
lower spine BMD than femoral neck BMD). We followed
the hypothesis that the fracture risk for a given patient could
lead to a different FRAX® outcome when a difference of at
least 1 SD exists between both BMDs of the neck and spine
[19]. None of our patients fulfilled this criterion.
Our study has several limitations. First, number of
patients in each age strata is small. Although our sample
size is relatively small, it is homogeneous and representative
of our inpatient population (median age, sex, and high
prevalence of hip fracture). Second, the FRAX® tool was
done to predict a 10-year probability risk of fracture and not
an immediate risk of fracture. However, a fracture occurring
the day after an evaluation is included in the 10-year prob-
ability. Third, we did not have a control population (non-
fractured patients) to calculate the sensitivity, specificity,
and positive/negative predictive values of the thresholds,
but our objective was not to propose new thresholds, only
to test it in a very high-risk population. Fourth, fall is notT
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evaluated in FRAX®, and it is possible that our population
was at high risk of fall. Finally, to be able to compare our
result with SVGO thresholds, we only considered the result
of FRAX® for major OF, not for hip fracture, in >50 % of
our population suffering from a hip fracture.
In summary, the current proposed Swiss thresholds were
not able to classify to be at high risk in 50 to 70 % of the
studied population the day before a major OF.
Disclosures None.
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